Roche’s Mircera Clears FDA, But U.S. Launch Appears Stalled

FDA approved Roche's long-acting erythropoiesis-stimulating agent Mircera for the treatment of anemia associated with chronic renal failure in adults Nov. 14, but a near-term launch of the product appears unlikely given Amgen's legal hold on the market